Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
NGM Biopharmaceuticals Inc banner
N

NGM Biopharmaceuticals Inc
F:0IK

Watchlist Manager
NGM Biopharmaceuticals Inc
F:0IK
Watchlist
Price: 3.19 EUR 3.91% Market Closed
Market Cap: €266.2m
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

0IK Price Targets Summary
NGM Biopharmaceuticals Inc

Wall Street analysts forecast 0IK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 0IK is 4.67 EUR with a low forecast of 3.53 EUR and a high forecast of 5.63 EUR.

0IK Lowest Forecast
Wall Street Target
3.53 EUR
11% Upside
0IK Average Forecast
Wall Street Target
4.67 EUR
47% Upside
0IK Highest Forecast
Wall Street Target
5.63 EUR
76% Upside
Lowest
Price Target
3.53 EUR
11% Upside
Average
Price Target
4.67 EUR
47% Upside
Highest
Price Target
5.63 EUR
76% Upside
NGM Biopharmaceuticals Inc Competitors:
Price Targets
C
CPNREIT
CPN Retail Growth Leasehold REIT
8% Upside
SYSR
Systemair AB
17% Upside
C
CPNREIT
CPN Retail Growth Leasehold REIT
8% Upside
SYSR
Systemair AB
17% Upside

Revenue
Forecast

18% / Year
Past Growth
18% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
18% / Year
Past Growth
18% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

For the last 2 years the compound annual growth rate for NGM Biopharmaceuticals Inc's revenue is 18%. The projected CAGR for the next 4 years is 18%.

What are analyst estimates?

Operating Income
Forecast

3% / Year
Past Growth
20% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
3% / Year
Past Growth
20% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

For the last 2 years the compound annual growth rate for NGM Biopharmaceuticals Inc's operating income is 3%. The projected CAGR for the next 4 years is 20%.

What are analyst estimates?

Net Income
Forecast

-17% / Year
Past Growth
7% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
-17% / Year
Past Growth
7% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

For the last 2 years the compound annual growth rate for NGM Biopharmaceuticals Inc's net income is -17%. The projected CAGR for the next 4 years is 7%.

What are analyst estimates?

See Also

Summary
0IK intrinsic value, competitors valuation, and company profile.
DCF Valuation
0IK stock valuation using Discount Cash Flow valuation method.
Relative Valuation
0IK stock valuation using valuation multiples.
Wall Street Estimates
0IK price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
0IK stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is 0IK's stock price target?
Price Target
4.67 EUR

According to Wall Street analysts, the average 1-year price target for 0IK is 4.67 EUR with a low forecast of 3.53 EUR and a high forecast of 5.63 EUR.

What is NGM Biopharmaceuticals Inc's Revenue forecast?
Projected CAGR
18%

For the last 2 years the compound annual growth rate for NGM Biopharmaceuticals Inc's revenue is 18%. The projected CAGR for the next 4 years is 18%.

What is NGM Biopharmaceuticals Inc's Operating Income forecast?
Projected CAGR
20%

For the last 2 years the compound annual growth rate for NGM Biopharmaceuticals Inc's operating income is 3%. The projected CAGR for the next 4 years is 20%.

What is NGM Biopharmaceuticals Inc's Net Income forecast?
Projected CAGR
7%

For the last 2 years the compound annual growth rate for NGM Biopharmaceuticals Inc's net income is -17%. The projected CAGR for the next 4 years is 7%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 318,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.